EGFR

New Hope for Long-Term Survival in Late-Stage Patients: Overview of Five Major Targeted Drugs and Clinical Trials for Non-Small Cell Lung Cancer

by
New Hope for Long-Term Survival in Late-Stage Patients: Overview of Five Major Targeted Drugs and Clinical Trials for Non-Small Cell Lung Cancer

EGFR In the Chinese patient population, EGFR is the most common driver gene mutation type in non-small cell lung cancer and is also one of the gene types with relatively good efficacy. However, even for this type of non-small cell lung cancer, there are still some “blind spots” in targeted therapy, such as certain difficult-to-treat … Read more

Understanding Bispecific Antibody Drug Conjugates (BsADCs)

by
Understanding Bispecific Antibody Drug Conjugates (BsADCs)

Introduction Antibody-drug conjugates (ADCs) consist of antibodies, linkers, and cytotoxic payloads. Compared to traditional chemotherapy, ADCs target tumors with the promise of reducing systemic toxicity, providing a broader therapeutic window and a higher therapeutic index. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary … Read more